Overcoming multidrug resistance (MDR) in cancer in vitro and in vivo by a quinoline derivative

Biomedicine and Pharmacotherapy

Volumn 65, Issue 6, 2011, Pages 387-394

  Ganguly, Avishek ^a   Banerjee, Kaushik ^a   Chakraborty, Paramita ^a   Das, Satyajit ^a   Sarkar, Avijit ^b   Hazra, Abhijit ^c   Banerjee, Maitrayee ^c   Maity, Arindam ^c   Chatterjee, Mitali ^b   Mondal, Nirup B ^c   Choudhuri, Soumitra Kumar ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^c INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Apoptosis; Multidrug resistance; Quinoline derivatives

Indexed keywords

2 (2 METHYL QUINOLIN 4YLAMINO) N PHENYL ACETAMIDE; ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; DOXORUBICIN; QUINOLINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL STRAIN HCT116; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; EHRLICH ASCITES TUMOR; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIFE EXTENSION; LYMPHATIC LEUKEMIA; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; T CELL LEUKEMIA;

ACETANILIDES; AMINOQUINOLINES; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; CARCINOMA, EHRLICH TUMOR; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MICE; NEOPLASMS; OXIDATIVE STRESS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REACTIVE OXYGEN SPECIES; SURVIVAL ANALYSIS; TOXICITY TESTS, CHRONIC;

EID: 80052657277     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.04.024     Document Type: Article

References (41)

1. Via L.D., Gia O., Gasparotto V., et al. Discovery of a new anilino-3H-pyrrolo[3,2-f]quinoline derivative as potential anti-cancer agent. Eur J Med Chem 2008, 43:429-434.
2. Hawtin R.E., Stockett D.E., Byl J.A.W., et al. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS ONE 2010, 5(4):e10186.
3. Ye W., Chang H.L., Wang L.S., et al. Modulation of multidrug-resistance gene expression in human breast cancer cells by (-)-gossypolenriched cottonseed oil. Anticancer Res 2007, 27:107-116.
4. Liscovitch M., Lavie Y. Cancer multidrug resistance: a review of recent drug discovery research. I Drugs 2002, 5:1-7.
5. Tsuruo T., Naito M., Tomida A., et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003, 94:15-21.
6. Chou T.C., Depew K.M., Zheng Y.H., et al. Reversal of anticancer multidrug resistance by the ardeemins. Proc Natl Acad Sci 1998, 95:8369-8374.
7. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS mediated mechanisms: a radical therapeutic approach?. Nat Rev Drug Discov 2009, 8:579-591.
8. Engel R.H., Evens A.M. Oxidative stress and apoptosis: a new treatment paradigm in cancer. Frontiers Biosci 2006, 11:300-312.
9. Ganguly A., Basu S., Chakraborty P., et al. Targeting mitochondrial cell death pathway to overcome drug resistance with a newly developed iron chelate. PLoS ONE 2010, 5(6):e11253.
10. Sahu N.P., Pal C., Mandal N.B., et al. Synthesis of a novel quinoline derivative, 2-(2-Methylquinolin-4-ylamino)-N-phenylacetamide - a potential antileishmanial agent. Bioorg Med Chem 2002, 10:1687-1693.
11. Mookerjee A., Basu J.M., Dutta P., et al. Overcoming drug-resistant in cancer by a newly developed copper chelate through host protective cytokine mediated apoptosis. Clin Cancer Res 2006, 12:4339-4349.
12. Majumder S., Dutta P., Mukherjee P., et al. Reversal of drug resistance in P-glycoprotein-expressing T-cell acute lymphoblastic CEM leukemia cells by copper N-(2-hydroxy acetophenone) glycinate and oxalyl bis (N-phenyl) hydroxamic acid. Cancer Lett 2006, 244:16-23.
13. Kimmig A., Gekeler V., Neumann M., et al. Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res 1990, 50:6793-6799.
14. Gillet J.P., Efferth T., Steinbach D., et al. Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res 2004, 64:8987-8993.
15. Efferth T., Sauerbrey A., Olbrich A., et al. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 2003, 64:382-394.
16. Muscella A., Greco S., Elia M.G., et al. Angiotensin II stimulation of Na/KATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells. J Endocrinol 2002, 173:315-323.
17. Mookerjee A., Basu J.M., Majumder S., et al. A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo. BMC Cancer 2006, 6:267-277.
18. Friche E., Danks M.K., Beck W.T. Characterization of tumor cell resistance to 4-deoxy-4-iododoxorubicin developed in Ehrlich Ascites cells in vitro. Cancer Res 1992, 52:5701-5706.
19. Choudhuri S.K., Chatterjee A. Reversal of resistance against doxorubicin by a newly developed compound, oxalyl bis(N-phenyl) hydroxamic acid in vitro. Anticancer Drugs 1998, 9:825-832.
20. Tsuoro T., Iisida H., Tsukagoshi S., et al. Overcoming vincristine resistance in P-388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine, vinblastin by verapamil. Cancer Res 1981, 41:1967-1972.
21. Vermes I., Haanen C., Steens-Nakken H., et al. A novel assay for apoptosis, flow cytometric detection of hosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995, 184:39-51.
22. Yang L., Wu S., Zhang Q., et al. 23,24-Dihydrocucurbitacin B induces G2/M cell-cycle arrest and mitochondria-dependent apoptosis in human breast cancer cells (Bcap37). Cancer Lett 2007, 256:267-278.
23. Chandra J. Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies. Antioxid Redox Signal 2009, 11:1123-1137.
24. Mizutani H., Tada-Oikawa S., Hiraku Y., et al. Mechanism of apoptosis induced by a new topoisomerase inhibitor through the generation of hydrogen peroxide. J Biol Chem 2002, 277:30684-30689.
25. Du J.Q., Wu J., Zhang H.J., et al. Isoquinoline-1,3,4-trione derivatives inactivate Caspase-3 by generation of reactive oxygen species. J Biol Chem 2008, 283:30205-30215.
26. Soha Y., Shin M.H., Lee J.S., et al. Oxidative DNA damage and glioma cell death induced by tetrahydropapaveroline. Mutat Res 2003, 544:129-142.
27. Hall M.D., Handley M.D., Gottesman M.M. Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci 2009, 30:546-556.
28. Horwedel C., Tsogoeva S.B., Wei S., et al. Cytotoxicity of artesunic acid homo- and heterodimer molecules toward sensitive and multidrug-resistant CCRF-CEM leukemia cells. J Med Chem 2010, 53:4842-4848.
29. Ikeda T., Sporn M., Honda T., et al. The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance. Cancer Res 2003, 63:5551-5558.
30. Lizard G., Gueldry S., Sordet O., et al. Glutathione is implied in the control of 7-ketocholesterol-induced apoptosis, which is associated with radical oxygen species production. FASEB J 1998, 12:1651-1663.
31. Liu W., Kato M., Akhand A.A., et al. 4-hydroxynonenal induces a cellular redox status-related activation of the caspase cascade for apoptotic cell death. J Cell Sci 2000, 113:635-641.
32. Deb I., Paira P., Hazra A., et al. Synthesis and characterizations of novel quinoline derivatives having mixed ligand activities at the κ and μ receptors: potential therapeutic efficacy against morphine dependence. Bioorg Med Chem 2009, 17:5782-5790.
33. Mondal S.K., Mondal N.B., Banerjee S., et al. Determination of drug like properties of a novel antileismanial compound: in vitro absorption, distribution, metabolism, and excretion studies. Indian J Pharmacol 2009, 41:176-181.
34. Clarke M.J. Ruthenium metalo pharmaceuticals. Coord Chem Rev 2003, 236:209-233.
35. Ghavami S., Hashemi M., Ande S.R., et al. Apoptosis and cancer: mutations within caspase genes. J Med Genet 2009, 46:497-510.
36. Slee E.A., Adrain C., Martin S.J. Executioner Caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem 2001, 276:7320-7326.
37. Lavoie J.N., Nguyen M., Marcellus R.C., et al. E4orf4, a novel adenovirus death factor that induces p53-independent apoptosis by a pathway that is not inhibited by zVAD-fmk. J Cell Biol 1998, 140:637-645.
38. Kravchenko D.V., Kuzovkova Y.A., Kysil V.M., et al. Synthesis and structure - activity relationship of 4-substituted 2-(2-Acetyloxyethyl)-8-(morpholine- 4-sulfonyl)pyrrolo[3,4-c]quinoline- 1,3-diones as potent Caspase-3 inhibitors. J Med Chem 2005, 48:3680-3683.
39. Lee D., Long S.A., Adams J.L., et al. Potent and selective nonpeptide inhibitors of Caspases 3 and 7 inhibit apoptosis and maintain cell functionality. J Biol Chem 2000, 275:16007-16014.
40. Hadad J. Redox and oxidant-mediated regulation of apoptosis signaling pathways: immuno-pharmaco-redox conception of oxidative siege versus cell death commitment. Int Immunopharmacol 2004, 4:475-493.
41. Trompier D., Chang X.B., Barattin R., et al. Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1. Cancer Res 2004, 64:4950-4956.